DMAC vs NVR · $157.4M cap vs P/E 15, rev $10.52B
DiaMedica Therapeutics Inc (DMAC) versus NVR Inc (NVR) — a side-by-side from cached financials, not a winner call.
DiaMedica Therapeutics Inc (DMAC) is a biotechnology company listed on US.
NVR Inc (NVR) is a residential construction company listed on NYSE.
DMAC does not have a complete income-statement cache yet.
Latest reported NVR revenue for 2024-12-31 was $10.52B. Net income was $1.68B. Revenue was up 10.6% from 2023-12-31 to 2024-12-31. NVR currently screens at market cap $16.94B and trailing P/E 15.3.
DMAC currently screens at market cap $157.4M. NVR currently screens at market cap $16.94B and trailing P/E 15.3.
Not investment advice. Open the DMAC and NVR stock pages for the full models.
Not investment advice.